Cambridge-based gene therapy developer bluebird bio said today it has been awarded $9.3 million from the California Institute for Regenerative Medicine to support a Phase 1/2 study for the company's product LentiGlobin, which is designed to treat a group of inherited blood disorders.
The study will be initiated in the United States next year.
LentiGlobin introduces a full functional human beta-globin gene into the patient's own hematopoietic stem cells, which ultimately produce fully functioning red blood cells. The company is currently conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in treating beta-thalassemia and sickle cell disease.
The CIRM award is among the first awards under the agency's Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and increase outside investment in CIRM-funded stem cell research.
Anda sedang membaca artikel tentang
Bluebird bio lands $9.3M for study
Dengan url
http://wartawanlocal.blogspot.com/2012/10/bluebird-bio-lands-93m-for-study.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Bluebird bio lands $9.3M for study
namun jangan lupa untuk meletakkan link
Bluebird bio lands $9.3M for study
sebagai sumbernya
0 komentar:
Posting Komentar